BCAL vs BSX · P/E 11, rev $226.0M vs P/E 20, rev $10.65B
Southern California Bancorp Common Stock (BCAL) versus Boston Scientific Corp (BSX) — a side-by-side from cached financials, not a winner call.
Southern California Bancorp Common Stock (BCAL) is a banks - regional company listed on NASDAQ.
Boston Scientific Corp (BSX) is a medical devices company listed on US.
Latest reported BCAL revenue for 2025-12-31 was $226.0M. Net income was $63.1M. Revenue was up 25.7% from 2024-12-31 to 2025-12-31. BCAL currently screens at market cap $628.2M and trailing P/E 10.7.
Latest reported BSX revenue for 2026-06-30 was $10.65B. Net income was $2.24B. BSX currently screens at market cap $71.81B and trailing P/E 20.2.
BCAL currently screens at market cap $628.2M and trailing P/E 10.7. BSX currently screens at market cap $71.81B and trailing P/E 20.2.
Not investment advice. Open the BCAL and BSX stock pages for the full models.
Not investment advice.